共 88 条
[1]
Bahn RS(2010)Graves’ ophthalmopathy N Engl J Med. 362 726-38
[2]
Bartalena L(2012)Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy J Clin Endocrinol Metab. 97 4454-63
[3]
Krassas GE(2015)Randomized controlled trial of rituximab in patients with graves’ orbitopathy J Clin Endocrinol Metab. 100 432-41
[4]
Wiersinga W(2018)Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial Am J Ophthalmol. 195 181-90
[5]
Marcocci C(2019)A new era in the treatment of thyroid eye disease Am J Ophthalmol. 208 281-8
[6]
Salvi M(2019)Thyroid eye disease: how a novel therapy may change the treatment paradigm Ther Clin Risk Manag. 15 1305-18
[7]
Daumerie C(2021)Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States Ophthalmol. Ther 10 75-87
[8]
Stan MN(2010)Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 62 199-236
[9]
Garrity JA(2015)Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins J Clin Endocrinol Metab. 100 1071-7
[10]
Leon BGC(2004)Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor J Clin Endocrinol Metab. 89 5076-80